With the in-depth study of the molecular biology of PEComa, molecular targeted therapy has gradually become a new direction in the treatment of PEComa, and the combination of two important molecularly targeted drugs, VEGFR inhibitors and immune checkpoint inhibitors, has a potential application in the treatment of PEComa. This evidence concerns the gene KDR and neoplasm with perivascular epithelioid cell differentiation.